Methotrexate shows modest benefits for hand osteoarthritis when inflammation is present, but it does not appear to help knee osteoarthritis. The answer depends heavily on which joint is affected and whether the joint lining is actively inflamed, a condition called synovitis.
Why Methotrexate Is Even Considered for OA
Methotrexate is best known as a cornerstone treatment for rheumatoid arthritis, an autoimmune condition where the immune system attacks the joints. Osteoarthritis is a different disease, driven primarily by cartilage breakdown and mechanical wear. But researchers have increasingly recognized that many people with OA also have significant inflammation in the joint lining, and that this inflammation contributes to pain and progression. That overlap is what sparked interest in testing methotrexate for OA.
The drug works by boosting levels of a signaling molecule called adenosine, which triggers a cascade of anti-inflammatory effects. It reduces the number of inflammatory cells migrating into the joint, suppresses key inflammation-driving proteins like TNF and IL-6, and shifts immune cells from a pro-inflammatory state to an anti-inflammatory one. In rheumatoid arthritis, these effects are powerful. The question has been whether they translate to osteoarthritis, where inflammation plays a supporting role rather than the lead.
Hand Osteoarthritis: A Small but Real Benefit
The strongest evidence in favor of methotrexate comes from the METHODS trial, a rigorous placebo-controlled study conducted across multiple sites in Australia. Researchers enrolled patients with hand osteoarthritis who also had confirmed synovitis (visible joint inflammation on imaging). Participants took methotrexate or a placebo for six months.
The methotrexate group saw their pain scores drop by about 15 points on a 100-point scale, compared to roughly 8 points in the placebo group. That 10-point difference was statistically significant, but it represents a moderate effect. In clinical terms, some participants likely noticed a meaningful improvement in daily hand function, while others may not have felt much difference. The effect size of 0.45 places it in the “small to moderate” range, similar to what you might expect from a consistent exercise program or certain topical anti-inflammatory treatments.
The key detail: this trial specifically selected patients with synovitis. Methotrexate targets inflammation, so it makes sense that it would only help when inflammation is a significant part of the problem. If your hand OA is primarily a cartilage and bone issue without much swelling, the drug is less likely to offer anything.
Knee Osteoarthritis: No Benefit Found
The picture for knee OA is clearer and less encouraging. The MESKO trial, conducted at 11 sites in China, enrolled 215 people with knee osteoarthritis who also had confirmed fluid buildup and synovitis on MRI. Participants took up to 15 mg of methotrexate weekly or a placebo for a full year.
After 52 weeks, both groups improved by almost identical amounts. Pain scores dropped about 29.5 points in the methotrexate group and 29.8 points in the placebo group. The drug also failed to reduce the amount of fluid or inflammation visible on MRI. None of the secondary outcomes (stiffness, physical function, imaging measures) showed any advantage over placebo. A review in Nature Reviews Rheumatology summarized the finding bluntly: methotrexate does not improve knee OA.
This result was somewhat surprising because the trial specifically targeted patients with inflammatory features, which is where methotrexate should theoretically have the best shot. The large placebo response (nearly 30 points of improvement) also suggests that regular medical attention, structured follow-up, and the expectation of treatment may account for much of the improvement people experience in knee OA trials regardless of the drug involved.
What the Pooled Evidence Shows
A 2025 systematic review pooled data from 15 randomized controlled trials involving nearly 1,600 participants with various forms of OA. Across all studies, methotrexate was associated with lower pain scores, better physical function, and less stiffness compared to placebo. However, these pooled numbers are heavily influenced by the mix of joints studied and study designs included. The overall signal is weak enough that most rheumatology guidelines still do not recommend methotrexate as a standard OA treatment.
The pattern that emerges from the combined research is consistent: when inflammatory OA of the hand is the target, there is a detectable benefit. When knee OA is the target, even in patients selected for inflammation, the benefit disappears.
What Treatment Looks Like
In the clinical trials, methotrexate was started at a low dose of 10 mg per week and gradually increased over six weeks, typically reaching 15 to 25 mg weekly depending on how well patients tolerated it. The minimum effective dose was 7.5 mg per week. All participants also took folic acid supplements (5 mg on the six days they were not taking methotrexate) to reduce side effects.
The most common side effect is nausea and general stomach upset. In one large review, about 30% of patients on low-dose methotrexate experienced gastrointestinal symptoms even with folic acid supplementation. Less commonly, the drug can cause cough or shortness of breath, and in rare cases, a serious lung reaction characterized by fever, breathing difficulty, and changes visible on chest imaging. Regular blood tests are standard practice during treatment to monitor liver function and blood cell counts.
Because of these monitoring requirements and the modest benefit seen even in the best-case scenario (hand OA with synovitis), methotrexate is not a first-line option for osteoarthritis. It occupies a niche role for people who have tried standard approaches like exercise, weight management, anti-inflammatory medications, and joint injections without adequate relief, and whose imaging shows active inflammation in the joint lining.
Why Hand and Knee OA Respond Differently
The divergence between hand and knee results likely reflects real biological differences between these joints. Hand OA, particularly the erosive subtype, tends to involve more intense synovial inflammation relative to the size of the joint. The inflammatory component may be a larger driver of pain in the hand than in the knee, where mechanical loading, cartilage loss, bone changes, and surrounding muscle weakness all contribute substantially to symptoms. A drug that specifically targets inflammation will naturally have more impact where inflammation is the dominant pain generator.
The knee also has a much larger joint volume, more complex biomechanics, and greater exposure to loading forces during daily activities. Even if methotrexate reduces some inflammation in the knee, the remaining mechanical and structural sources of pain may overshadow any anti-inflammatory benefit.